Plain-English translation of NCT07324707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new inhaled asthma medication called PA9159 to see if it works well and is safe for adults with asthma. About 30 people will participate, with half receiving the new medication and half receiving a standard asthma treatment (fluticasone propionate) over 28 days. Researchers will compare how well each treatment works and monitor for any side effects.
Asthma is a common condition that affects many adults, and doctors are always looking for better treatment options. This trial will help determine whether this new medication might offer patients another safe and effective choice for managing their asthma symptoms.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will visit the study center for screening and baseline tests, then be randomly assigned to receive either the new medication PA9159 or a standard asthma treatment (fluticasone propionate). You will use your assigned inhaler twice daily—two puffs in the morning and two puffs in the evening—for 28 days. The total study duration is about 42 days, including initial screening, the 28-day treatment period, and follow-up visits where researchers will monitor your asthma control and check for any side effects.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Anhui Palo Alto Pharmaceuticals, Inc.
Enrollment target
~30 participants
Started
October 2025
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mengli Kan
The First Affiliated Hospital of Nanchang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.